A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Clinical trial NCT02211846 · COMPLETED

Trial details

NCT number

NCT02211846

Sponsor

Astellas Pharma Inc

Status

COMPLETED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2014-09-21

Primary completion

2015-09-21

Enrollment

34

View on ClinicalTrials.gov